Strategic Acquisition Industry consolidation signals growth potential as PROGEN was recently acquired by Yuhan USA, suggesting expanded distribution channels and customer access. Leverage the expanded footprint to propose cross sell of Premium antibodies, AAV tools, and LNP delivery kits to a broader North American and global audience.

AAV Leadership Strong emphasis on AAV analytical tools and viral titer assays positions PROGEN as a go-to partner for gene therapy developers. Target gene therapy CROs, biotech startups, and academic labs expanding AAV workflows with Simple Plex assays and capsid quantification solutions.

Lifecycle Support PROGEN focuses on customer collaboration and specialized support beyond products. Sales opportunities exist in offering end-to-end solutions, training, and ongoing technical support bundled with kits, antibodies, and proteins to improve research success rates.

Product Portfolio Portfolio spans antibodies optimized for gene therapy, LNP delivery kits, and proteins for life sciences research, plus standard reagents for AAV analysis. Upsell opportunities include combined kits for gene therapy validation, multiplex antibody panels, and validated controls.

Global Reach Founded in Germany with global collaborations and recent distribution developments through Thermo Fisher and other partners indicate accessible international supply. Pitch regionalized solutions, regulatory-compliant materials, and local inventory to multinational biotech and pharma accounts.